MRKR - Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference | Benzinga
HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
Dr. Vera will provide an overview of Marker's advancements and clinical development programs on Wednesday, September 13, 2023, at 8:30 a.m. EDT. Of note, Marker believes its therapies are superior to CAR T cells because Marker's therapies use cancer killing T cells that are not genetically engineered and have more ways to recognize cancer cells than what is possible with current CAR T cell therapies.
During the conference, Dr. Vera and members of Marker will conduct one-on-one meetings with registered investors.
Details of the presentation are as follows:
| Event: |
| H.C. Wainwright 25th Annual Global Investment Conference |